Oncocyte CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Insight Molecular Diagnostics Inc. (IMDX) filed its Q2 2026 Form 10-Q, revealing a substantial decrease in net revenue and an increase in operating expenses, leading to a wider net loss.
Insight Molecular Diagnostics Inc. reported a reduced net loss for Q3 2025, driven by increased revenue and a significant capital raise, while advancing its diagnostic pipeline and expanding its global footprint.
Insight Molecular Diagnostics Inc. reports significant revenue growth and a strengthened cash position following a successful capital raise, despite continued operating losses.
Oncocyte Corporation's Q1 2025 net revenue increased significantly due to growth in Pharma Services, while the net loss decreased compared to the same period last year.
Oncocyte Corporation reported a net loss of $13.5 million in Q3 2024, a 108% increase from the same period last year, as the company pivots towards commercializing its transplant diagnostic tests.
Oncocyte Corporation's Q2 2024 results show a decrease in revenue and a significant increase in net loss, alongside strategic changes and a focus on commercializing transplant products.
Oncocyte Corporation's first quarter 2024 results show a net loss of $9.1 million, impacted by decreased revenue and changes in contingent consideration, while the company focuses on strategic shifts and new collaborations.